Author Archives | Simplyjo
Simplyjo - who has written 81 posts on FavStocks.
I have done by Post Graduation in Tourism from College of Vocational Studies apart from a full time MBA degree in Finance.I have worked with several reputed companies including IBM, MakeMyTrip and Habitat World.
I love to read, write and travel.
Currently, I am a SAHM ,earning a living off the stock market and making a killing with forex trades. I am sharing my knowledge so as to help others learn and expand their horizon.
Rosetta Genomics’ Diagnostic Program Update (NASDAQ:ROSG)
Rosetta Genomics (NASDAQ:ROSG) today announced an update regarding their colon cancer diagnostic program and said that Ayelet Chajut, Executive Vice President, R&D, Head of Molecular Biology will speak more about this program at the 6th International Conference on Circulating Nucleic Acids in Plasma and Serum (CNAPS-VI).
Continue reading...Geron Will Re-initiate Clinical Trials (NASDAQ:GERN)
30 October 2009
Comments Off
Geron Corporation (NASDAQ:GERN) today announced that they have reached an agreements with the Food and Drug Administration to re-initiate clinical trials for spinal cord injury.
Continue reading...Dynavax with new HEPLISAV Data (NASDAQ:DVAX)
30 October 2009
Comments Off
In one of the most surprising news today, Dynavax Technologies Corporation (NASDAQ:DVAX) has announced that the first clinical data of their HEPLISAV has shown increase in the protection rate for chronic kidney disease patients. The data will be presented publicly in a poster session on Saturday, October 31, 2009 at the Annual Meeting of the Infectious [...]
Continue reading...Celera’s New Agreement With Laboratory Service (NASDAQ:CRA)
29 October 2009
Comments Off
Berkeley HeartLab, a subsidiary of Celera Corporation (NASDAQ:CRA) announced today that they have entered into a collaborative agreements with Geisinger Medical Center and Proven Diagnostics, a clinical laboratory service launched by Geisinger Health System recently.
Continue reading...Theravance’s New Horizon (THRX, GSK)
28 October 2009
Comments Off
Theravance, Inc. (NASDAQ:THRX) today announced that they have commence Phase 3 of Horizon programme with GlaxoSmithKline plc (ADR) (NYSE:GSK)Â to develop a next generation treatment for COPD.
Continue reading...ZymoGenetics receives milestone payment
28 October 2009
Comments Off
ZymoGenetics, Inc. (NASDAQ:ZGEN) announced the initiation of a Phase 2 clinical trial of PEG-Interferon lambda (IL-29) and ribavirin in treatment naive patients with chronic hepatitis C virus (HCV) infection.
Continue reading...Arena Pharmaceuticals New Data (NASDAQ:ARNA)
28 October 2009
Comments Off
Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) announced new findings today, adding to the previously announced top line BLOSSOM data that showed highly significant weight loss with lorcaserin over one year of treatment in about four thousand patients.
Continue reading...Orexigen’s New Data (NASDAQ:OREX)
28 October 2009
Comments Off
Orexigen Therapeutics, Inc. (NASDAQ:OREX) has announced and presented their new data from the COR diabetes trials for Contrave to expand on top line results announced in July this year.
Continue reading...Sanofi drags Hospira and Apotex (NYSE:SNY)
27 October 2009
Comments Off
Sanofi-Aventis SA (ADR) (NYSE:SNY), France’s biggest pharmaceutical group has accused Hospira Inc and Canada’s Apotex Inc of infringing patents for the cancer drug Taxotere.
Continue reading...Theravance Milestone Payment (NASDAQ:THRX)
26 October 2009
Comments Off
Theravance, Inc. (NASDAQ:THRX) has announced that they have received a US$20 million milestone payment after their new drug telavancin was approved by the Food and Drug Administration panel.
Continue reading...
30 October 2009
Comments Off